If you want to see how biotech can change the world of health, whilst being capable of creating extraordinary value for investors, there are few better places to look than Amgen, one of the world’s leading independent biotech companies, with a market capitalisation of approximately $130bn.
If you want to see how biotech can change the world of health, whilst being capable of creating extraordinary value for investors, there are few better places to look than Amgen, one of the world’s leading independent biotech companies, with a market capitalisation of approximately $130bn.
In this conversation, Bob discusses the big areas of medical need, from cardiovascular problems which continue to make it the world’s greatest killer, through to genetics, obesity, osteoporosis and cancers.
Bob discusses timelines and priorities, the use of A.I. in accelerating drug development, biologics, facing setbacks on the road to approvals, and the challenge of running a company which has a presence in over 100 countries.
Never miss an episode
Be the first to listen to new episodes and receive a breakdown of the key points discussed.
_result.webp)
.png)
